Loading
institutionsInstitution
Mayo Clinic Comprehensive Cancer Center in Arizona
Mayo Clinic's Arizona campus, spanning Phoenix and Scottsdale, is one of three sites under Mayo's NCI comprehensive designation; it opened a proton therapy centre in 2016, runs bone marrow transplant, CAR-T and a myeloma programme, and hosts Mayo's Arizona early-phase trials under Tanios Bekaii-Saab.
Also called: Mayo Clinic PhoenixMayo Clinic Scottsdale
Overview
Mayo Clinic Arizona, spanning the Phoenix hospital and Scottsdale clinic, is one of the three campuses covered by Mayo Clinic Comprehensive Cancer Center's NCI designation. Its proton beam therapy centre opened in 2016, and the campus runs bone marrow transplant, CAR-T and a myeloma programme built by A. Keith Stewart and Rafael Fonseca. Tanios Bekaii-Saab leads GI oncology and Mayo's Arizona early-phase trials, and the Mayo Clinic Alix School of Medicine and an alliance with Arizona State University support research in medical technology and data science. The campus serves patients across the south-western US.
Location
Phoenix, AZ, US
Type
hospital
Newsweek 2026 oncology rank
Not in top 300 listing used
NCI designation
comprehensive
OnCo score
#149 · 33 points (0 Newsweek + 15 NCI + 18 from 9 linked objects) · ranking
- Proton therapy
- Multiple myeloma
- GI oncology and phase 1 trials
A. Keith Stewart
Director, Princess Margaret Cancer Centre; Vice President, Cancer, University Health Network
Multiple myelomaCancer genomicsAcademic leadership
Keith Stewart is a myeloma researcher who leads Canada's largest cancer centre.
Aleksandar Sekulic
Dermatologist, Mayo Clinic Comprehensive Cancer Center in Arizona
Basal cell carcinomaHedgehog pathway inhibitorsSkin cancer
Mayo Clinic dermatologist who led ERIVANCE, the trial that established vismodegib, the first Hedgehog pathway inhibitor, for advanced basal cell carcinoma.
Tanios Bekaii-Saab
Professor of Medicine; Leader, GI Cancer Program, Mayo Clinic Arizona
Gastrointestinal oncologyColorectal cancerBiliary cancer
GI oncologist behind trials of KRAS, HER2, and FGFR-directed therapy in colorectal and bile duct cancer.
Similar pages
- InstitutionUniversity of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Shares NCI-Designated Cancer Centers, Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Proton therapy, National Cancer Institute (NIH).
- InstitutionMayo Clinic Comprehensive Cancer Center in Florida
Shares NCI-Designated Cancer Centers, Mayo Clinic, Proton therapy, National Cancer Institute (NIH).
- InstitutionThe University of Kansas Cancer Center
Shares NCI-Designated Cancer Centers, Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Proton therapy, National Cancer Institute (NIH).
- InstitutionO'Neal Comprehensive Cancer Center at UAB
Shares NCI-Designated Cancer Centers, Proton therapy, National Cancer Institute (NIH), Pancreatic ductal adenocarcinoma.
- InstitutionSylvester Comprehensive Cancer Center, University of Miami
Shares Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Proton therapy, National Cancer Institute (NIH), Multiple myeloma.
- InstitutionMUSC Hollings Cancer Center
Shares NCI-Designated Cancer Centers, Proton therapy, National Cancer Institute (NIH), Colorectal cancer.
- InstitutionUniversity of Florida Health Cancer Center
Shares NCI-Designated Cancer Centers, Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Proton therapy, National Cancer Institute (NIH).
- InstitutionVCU Massey Comprehensive Cancer Center
Shares NCI-Designated Cancer Centers, National Cancer Institute (NIH), Multiple myeloma.